Exacerbation of respiratory symptoms in patients with panic disorder.
Bouwer
C D
CD
Stein
D J
DJ
Hawkridge
S M
SM
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000208:Acute Disease; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002216:Captopril / Q000009:adverse effects; D017315:Cilazapril / Q000009:adverse effects; D015283:Citalopram / Q000494:pharmacology / Q000627:therapeutic use*; D015897:Comorbidity; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000188:drug therapy* / Q000453:epidemiology; D012120:Respiration Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020280:Sertraline
D015057:1-Naphthylamine; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002216:Captopril; D017315:Cilazapril; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline